

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON2		SERIAL NO.: 10/056,340						
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH et al.		GROUP: 1639						
				FILING DATE: January 25, 2002								
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA											
	AB											
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
												YES NO
	AC											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
	AD	Statement Before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the Nonsteroidal anti-inflammatory Drug Celecoxib. (HRG Publication #1465); December 1, 1998; obtained from http://www.citizen.org/publications/print_release.cfm?ID=6653 on October 28, 2008.										
	AE	NDA 020938 Approval letter and label April 13, 2000; obtained from http://www.accessdata.fda.gov on October 16, 2008										
	AF	NDA 20-938 Medical Review, completed August 31, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008										
	AG	NDA 20-938 Pharmacology Review(s), completed September 17, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008										
	AH	NDA 20-938 Clinical Pharmacology and Biopharmaceutics Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008										
	AI	NDA 20-938 Correspondence, 1998-1999; obtained from http://www.accessdata.fda.gov on October 16, 2008										
	AJ	NDA 20-938 Administrative Documents, 1998; obtained from http://www.accessdata.fda.gov on October 16, 2008										
	AK	NDA 20-938 Chemistry Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008										
	AL	NDA 20-938 Microbiology Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008										
	AM	NDA 20-938 Statistical Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008										
	AN	Therapeutics Initiative, February 1995										
	AO	Therapeutics Initiative, January 1997										
	AP	Therapeutics Initiative, January/February 2001										
	AQ	Prescribing Points, volume 8.4, June 1999										
	AR											
	AS											
EXAMINER		/Christopher Gross/ (07/07/2009)						DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: /CG/